Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study

结直肠癌预后的跨学科团队科学：ColoCare 研究

• 批准号: 10696206
• 负责人: Jane C. Figueiredo
• 金额: $ 184.87万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-19 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10696206
• 关键词: Acceleration; Address; Ancillary Study; Behavioral; Biological Markers; Blood; Blood specimen; Cancer Prognosis; Cancer Survivorship; Cessation of life; Clinical; Clinical Data; Cohort Studies; Collaborations; Collection; Colorectal Cancer; Communities; Data; Data Reporting; Decision Making; Development; Diagnosis; Disparity; Enrollment; Epidemic; Ethnic Origin; Feces; Geography; Grant; Infrastructure; Institution; Interdisciplinary Study; Intervention; Knowledge; Life Style; Maintenance; Malignant Neoplasms; Medical; Medical Records; Modality; Molecular; Newly Diagnosed; Outcome; Paper; Participant; Patient Outcomes Assessments; Patient Participation; Patient Recruitments; Patient Self-Report; Patients; Population; Population Heterogeneity; Productivity; Prognosis; Protocols documentation; Publishing; Questionnaires; Race; Rectal Cancer; Recurrence; Research; Research Personnel; Resources; Risk; Rural Population; Sample Size; Sampling; Science; Scientific Advances and Accomplishments; Secure; Site; Standardization; Time; Tissue Sample; Tumor Tissue; Underserved Population; Urine; Woman; Work; anticancer research; biobank; blood-based biomarker; cancer health disparity; cohort; colon cancer patients; colorectal cancer treatment; data harmonization; data repository; data sharing; data warehouse; design; early onset colorectal cancer; epidemiologic data; ethnic minority; experience; follow-up; gut microbiome; improved; indexing; innovation; interest; men; microbiome; neoplasm registry; neoplasm resource; new therapeutic target; novel; novel marker; novel therapeutics; patient engagement; patient population; prospective; racial diversity; racial minority; recruit; sample collection; stem; stool sample; survivorship; translational study

SUMMARY Colorectal cancer (CRC) is the second most common cancer among men and women in the U.S., leading to over 50,000 deaths per year. Research aimed at reducing CRC’s high burden, discovering/validating novel biomarkers associated with prognosis, addressing the growing epidemic of early-onset CRC, and countering CRC disparities in underserved populations is of pressing importance. CRC patient cohorts that include diverse populations and longitudinally ascertain clinical data and biospecimens are essential for pursuing these critical objectives. The ColoCare Study is a large, multi-institutional prospective survivorship cohort that enrolls newly diagnosed patients with CRC from diverse racial/ethnic and geographic backgrounds. CRC survivorship cohorts are rare and ColoCare is unique given its collection of detailed epidemiologic and clinical data and a variety of biospecimens at multiple time points. This design enables innovative survivorship research that spans lifestyle/behavioral factors, racial/ethnic CRC disparities, and translational studies aimed at discovering and validating novel molecular, blood- and microbiome-based biomarkers related to the risk of adverse CRC outcomes. Such research can inform treatment decision-making, interventions aimed at improving key clinical and patient reported outcomes, and the development of novel therapeutics. The ColoCare Study has enrolled >3,000 patients with a median of 2.1 years of follow-up and biospecimen collections including tumor tissue and serial blood, stool, and urine samples. Despite being a young cohort, ColoCare has already supported 70 published papers and 79 projects that include 72 external investigators. Continued U01 infrastructure support is critical to sustain and grow this valuable resource for CRC survivorship research. Here, we will pursue the following aims: (1) Increase the size of the cohort from 3,361 to 4,157 participants, including enhanced recruitment of underserved and understudied populations who experience significant disparities in CRC outcomes, and patients receiving novel therapies. (2) Extend participant follow-up to 5-years through both active follow-up (biospecimens; questionnaires; medical record abstractions) and passive follow-up (SEER/state cancer registries and National Death Index). (3) Maintain and expand the ColoCare biorepository, including collection of tumor tissue samples and longitudinal collections of blood and stool samples. (4) Maintain and expand the ColoCare Central Data Warehouse, the capabilities of our study portal to encourage and facilitate requests from external and internal investigators, and engagement with our Community Advisory Board to advance patient participation and the public dissemination of knowledge generated by ColoCare. With continued infrastructure support, this unique and comprehensive resource will continue to enable a wide-range of impactful colorectal cancer survivorship research.

概括 结直肠癌（CRC）是美国男性和女性中第二常见的癌症，导致 每年超过50,000人死亡。旨在减少CRC高燃烧，发现/验证小说的研究 与预后相关的生物标志物，解决早期CRC的流行病以及反对 服务不足人群中的CRC差异非常重要。 CRC患者队列，包括潜水员 人群和纵向确定的临床数据和生物测量对于追求这些关键至关重要 目标。 Colocare研究是一项大型的，多机构的前瞻性表面同类群体，可招收新的 诊断出来自潜水员种族/种族和地理背景的CRC患者。 CRC幸存者 同类人群很少见，鉴于其收集了详细的流行病学和临床数据以及A 多种时间点的生物测量种类。该设计使创新的生存研究能够 跨越生活方式/行为因素，种族/族裔CRC分布以及旨在发现的翻译研究 并验证与广告CRC风险有关的新型分子，血液和微生物组的生物标志物 结果。此类研究可以为治疗决策提供信息，旨在改善关键临床的干预措施 患者报告的结果以及新疗法的发展。 Colocare研究已招募了3,000名患者，中位为2。1年的随访和生物循环。 包括肿瘤组织和系列血液，粪便和尿液样品在内的收集。尽管是一个年轻的队列， Colocare已经支持70篇已发表的论文和79个项目，其中包括72名外部调查人员。 持续的U01基础设施支持对于维持和发展这一宝贵的CRC生存资源至关重要 研究。在这里，我们将追求以下目的：（1）将队列的规模从3,361增加到4,157 参与者，包括加强服务不足和理解的人群的招聘 CRC结局的显着差异以及接受新疗法的患者。 （2）扩展参与者的随访 通过主动随访（Bispecimens;问卷调查；医疗记录摘要）和5年 被动后续行动（先知/州癌症注册和国家死亡指数）。 （3）维护和扩展 Colocare Biorepository，包括肿瘤组织样本的收集以及血液的纵向收集和 粪便样品。 （4）维护和扩展Colocare Central Data Warehouse，我们研究的功能 门户以鼓励和促进外部和内部调查人员的要求，并与我们的参与 社区咨询委员会，以提高患者参与和公众对知识的传播 由Colocare生成。通过持续的基础设施支持，这种独特而全面的资源将 继续实现广泛的有影响力的大肠癌生存研究。

项目成果

Postoperative Complications Are Associated with Long-Term Changes in the Gut Microbiota Following Colorectal Cancer Surgery.

• DOI: 10.3390/life11030246
• 发表时间: 2021-03-16
• 期刊: Life (Basel, Switzerland)
• 作者: Schmitt FCF;Schneider M;Mathejczyk W;Weigand MA;Figueiredo JC;Li CI;Shibata D;Siegel EM;Toriola AT;Ulrich CM;Ulrich AB;Boutin S;Gigic B
• 通讯作者: Gigic B

Suitability of circulating miRNAs as potential prognostic markers in colorectal cancer.

• DOI: 10.1158/1055-9965.epi-14-0556
• 发表时间: 2014-12
• 期刊: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
• 作者: Ristau J;Staffa J;Schrotz-King P;Gigic B;Makar KW;Hoffmeister M;Brenner H;Ulrich A;Schneider M;Ulrich CM;Habermann N
• 通讯作者: Habermann N

Age-related differences in employment, insurance, and financial hardship among colorectal cancer patients: a report from the ColoCare Study.

结直肠癌患者在就业、保险和经济困难方面与年龄相关的差异：来自 ColoCare 研究的报告。

• DOI: 10.1007/s11764-023-01362-9
• 发表时间: 2023
• 期刊: Journal of cancer survivorship : research and practice
• 作者: Berghuijs,KarelyMvanThiel;Kaddas,HeydonK;Trujillo,Gillian;Rouhani,Gazelle;Chevrier,Amy;Ose,Jennifer;Shibata,David;Toriola,AdetunjiT;Figueiredo,JaneC;Peoples,AnitaR;Li,ChristopherI;Hardikar,Sheetal;Siegel,ErinM;Gigic,Bil
• 通讯作者: Gigic,Bil

Calorie restriction improves metabolic state independently of gut microbiome composition: a randomized dietary intervention trial.

• DOI: 10.1186/s13073-022-01030-0
• 发表时间: 2022-03-14
• 期刊: Genome medicine
• 影响因子: 12.3
• 作者: Sowah SA;Milanese A;Schübel R;Wirbel J;Kartal E;Johnson TS;Hirche F;Grafetstätter M;Nonnenmacher T;Kirsten R;López-Nogueroles M;Lahoz A;Schwarz KV;Okun JG;Ulrich CM;Nattenmüller J;von Eckardstein A;Müller D;Stangl GI;Kaaks R;Kühn T;Zeller G
• 通讯作者: Zeller G

Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer.

• DOI: 10.3390/cancers13184547
• 发表时间: 2021-09-10
• 期刊: Cancers
• 影响因子: 5.2
• 作者: Gong J;Hendifar A;Gangi A;Zaghiyan K;Atkins K;Nasseri Y;Murrell Z;Figueiredo JC;Salvy S;Haile R;Hitchins M
• 通讯作者: Hitchins M